Status:
COMPLETED
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Alopecia Areata
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After c...
Eligibility Criteria
Inclusion
- Subjects voluntarily sign the informed consent form.
- Patients who participated in ZGJAK018.
Exclusion
- Subjects who are unsuitable to the trial, as identified by the investigator.
Key Trial Info
Start Date :
March 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2024
Estimated Enrollment :
315 Patients enrolled
Trial Details
Trial ID
NCT05255237
Start Date
March 25 2022
End Date
June 28 2024
Last Update
March 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
11 Xizhimen South Street
Beijing, Beijing Municipality, China